GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (NAS:MRVI) » Definitions » Net Income

Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Net Income : $-119.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Maravai LifeSciences Holdings Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Maravai LifeSciences Holdings's Net Income for the three months ended in Dec. 2023 was $-106.0 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-119.0 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Maravai LifeSciences Holdings's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.80.


Maravai LifeSciences Holdings Net Income Historical Data

The historical data trend for Maravai LifeSciences Holdings's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maravai LifeSciences Holdings Net Income Chart

Maravai LifeSciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
Get a 7-Day Free Trial -8.49 76.89 182.04 220.21 -119.03

Maravai LifeSciences Holdings Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.63 -0.07 -6.54 -6.46 -105.96

Maravai LifeSciences Holdings Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Maravai LifeSciences Holdings's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=617.736+-756.111+0+19.346
=-119.0

Maravai LifeSciences Holdings's Net Income for the quarter that ended in Dec. 2023 is calculated as

Net Income(Q: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=656.186+-766.168+0+4.023
=-106.0

Net Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-119.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Maravai LifeSciences Holdings  (NAS:MRVI) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Maravai LifeSciences Holdings's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Maravai LifeSciences Holdings Net Income Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Business Description

Traded in Other Exchanges
Address
10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Executives
John A Deford director C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Rebecca Buzzeo officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Andrew Burch officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Martin William E. Iii officer: See remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Peter Michael Leddy officer: See Remarks 1620 FARADAY AVE, CARLSBAD CA 92008
Carl Hull director, officer: Chief Executive Officer 300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kurt Oreshack officer: General Counsel 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Murali Prahalad director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Lisa Sellers officer: See Remarks 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Susannah Gray director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Robert B Hance director 300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Brian Neel officer: See Remarks 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Christine Dolan officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121